Global Medtech UAE Healthcare Investment Basket 2025
The United Arab Emirates is making significant investments to upgrade its medical infrastructure, aiming to become a global healthcare destination. This basket provides exposure to the international US and EU-listed companies in pharmaceuticals, medtech, and digital health that supply this ambitious national project.
Your Basket's Financial Footprint
This basket's total market capitalisation is 1,715,711.323 (as provided) and is dominated by large-cap holdings that anchor its profile. That concentration implies generally lower volatility and closer tracking of broad-market moves.
- Large-cap dominance tends to lower volatility and produce steadier performance, aligning with broad-market movements rather than sharp swings.
- Suitable as a core holding for portfolio diversification; not intended as a short-term speculative trade.
- Expect steady long-term value; explosive short-term gains are less likely with concentrated large-cap exposure.
JNJ: $466.99B
PFE: $145.04B
AZN: $275.08B
- Other
About This Group of Stocks
Our Expert Thinking
The UAE is investing billions to transform its healthcare system into a world-class destination for medical tourism and advanced care. This ambitious national project relies heavily on international expertise and cutting-edge technology from global leaders in pharmaceuticals, medical devices, and digital health solutions.
What You Need to Know
This group focuses on established US and EU-listed companies that are directly supplying the UAE's healthcare modernisation. These are proven industry leaders with existing partnerships and operations in the region, offering exposure to this significant infrastructure development through the global supply chain perspective.
Why These Stocks
Each company was handpicked based on their direct involvement in the UAE's healthcare transformation. From AstraZeneca's research partnerships with Abu Dhabi to GE HealthCare's equipment supply agreements with the Ministry of Health, these stocks represent the key enablers of this national development initiative.
Why You'll Want to Watch These Stocks
Massive Infrastructure Spend
The UAE is investing billions in new hospitals and medical facilities, creating enormous demand for the advanced equipment and services these companies provide.
Medical Tourism Hub Ambitions
As the UAE positions itself as a global healthcare destination, these international suppliers stand to benefit from sustained, long-term growth in medical infrastructure.
Proven Regional Partnerships
These aren't speculative plays - each company already has established operations, partnerships, and supply agreements with UAE healthcare authorities and major hospital groups.
Get the full story on this Basket. Read our detailed article on its risks and potential.
Why Invest with Nemo Money?
Zero Commission
Trade stocks, ETFs, and more with zero commission. Keep more of your returns.
Trusted & Regulated
Part of Exinity Group 2015, serving over a million customers globally.
6% Interest on Cash
Earn 6% AER on uninvested cash with daily interest payments.
Discover More Opportunities
Beverage Stocks: What's Next After Coca-Cola's Pivot
Coca-Cola is discontinuing its historic Minute Maid frozen products to focus on faster-growing beverage categories. This strategic shift highlights a broader investment opportunity in companies leading the market's transition toward healthier, more convenient, and functional drinks.
Factory Automation Stocks | Rising Labor Costs Trend
Volkswagen's recent agreement with the UAW signals a new era of rising labor costs for foreign automakers in the U.S. This theme focuses on companies poised to benefit as the industry increases investment in factory automation and robotics to enhance productivity.
Blood Thinner Breakthrough Explained | Market Overview
Bayer's successful Phase III trial for its new blood thinner has demonstrated a significant reduction in stroke recurrence. This breakthrough positions the company favorably against competitors and highlights an investment opportunity in the evolving landscape of cardiovascular treatments.